Glenmark To Commercialise Beigenes Oncology Medicines In India

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Glenmark to Commercialise BeiGene’s Oncology Medicines in India

ri-calendar-2-lineMay 21, 2024

By: BlinkX Research Team

FbkFbkTwitterTelegram

Glenmark Pharmaceuticals on Tuesday said its subsidiary Glenmark Speciality S.A. (Glenmark) signed an exclusive marketing and distribution agreement with BeiGene. Glenmark will register and commercialise BeiGene’s oncology medicines, Tislelizumab and Zanubrutinib in India. 

 

Key Takeaways from Glenmark Pharmaceuticals:

 

  • Glenmark signed an exclusive marketing and distribution agreement with BeiGene.
  • Glenmark will register and commercialise BeiGene’s oncology medicines, Tislelizumab and Zanubrutinib in India. 
  • Glenmark will be responsible for locally required development, registration, and distribution.

 

Tislelizumab is a novel anti-PD-1 monoclonal antibody approved by NMPA, EMA and FDA for treating advanced or metastatic oesophagal squamous cell carcinoma and various types of cancers as well. While Zanubrutinib, a BTK inhibitor is used in the treatment of certain hematological malignancies.

 

Under this collaboration, Glenmark will be responsible for locally required development, registration, and distribution leveraging BeiGene's innovative oncology medicines for cancer patients across India.

 

The partnership will help many low-and middle-income countries, including India, overcome the burden of cancer. Statistically, India has the third highest number of cancer cases worldwide. Currently, cancer claims approximately 900,000 lives annually in India.

 

About Glenmark Pharmaceuticals Limited:

Glenmark Pharmaceuticals Limited is a research-led, global pharmaceutical company with a presence across branded, generic, and OTC segments. The company focuses on therapeutic areas of respiratory, dermatology, and oncology. It has 11 world-class manufacturing facilities across four continents, and operations in over 80 countries. 

 

Read More About Glenmark Pharmaceuticals Limited Share Price Here!

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions